

September 19, 2024

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Palivizumab (Synagis)

We refer to our earlier communication dated September 30, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Palivizumab (Synagis) solution for injection 100 mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL presentations in single-dose vials administered through intramuscular route).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Palivizumab (Synagis) in October 2024 in India.

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:

- Infants born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
- Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia (BPD) within the last 6 months.
- Children less than 2 years of age and with hemodynamically significant congenital heart disease (CHD).

We request you to kindly take the above on records.

Thanking You,

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary